适应性设计随机对照临床试验

doi:10.3969/j.issn.1673-5765.2022.10.019

摘要/Abstract

摘要： 近年来，适应性设计因其灵活性和高效率而在临床试验中得到了广泛的应用。在实践中，适应性设计可以为研究者提供第二次机会，在研究进行中调整试验设计。本文将重点从历史渊源、基本概念、设计类型、设计特点、案例解读、统计分析及报告规范等方面对适应性设计进行简要介绍。

关键词: 适应性设计; 临床试验; 成组序贯试验; 随机对照

Abstract: In recent years, adaptive design has been widely used in clinical trials due to its flexibility and efficiency. In practice, adaptive design can give researchers a second chance to adjust the trial design during the study. This article briefly introduced historical origins, basic concepts, design types, design characteristics, case analysis, statistical methods, and reporting standards of adaptive design.

Key words: Adaptive design; Clinical trial; Group sequential trial; Randomized controlled trial

杨凯璇, 周齐, 姜英玉, 谷鸿秋. 适应性设计随机对照临床试验[J]. 中国卒中杂志, 2022, 17(10): 1152-1158.

YANG Kaixuan, ZHOU Qi, JIANG Yingyu, GU Hongqiu. Adaptive Design Randomized Controlled Clinical Trials [J]. Chinese Journal of Stroke, 2022, 17(10): 1152-1158.

参考文献

1] PALLMANN P，BEDDING A W，CHOODARI-OSKOOEI B，et al. Adaptive designs in clinical trials：why use them，and how to run and report them[J]. BMC Med，2018，16（1）：29.
[2] BHATT D L，MEHTA C. Adaptive designs for clinical trials[J]. N Engl J Med，2016，375（1）：65-74.
[3] Food and Drug Administration. Challenge and opportunity on the critical path to new medical products[EB/OL].（2018-01-25）[2022-08-10]. http://wayback.archive-it.org/7993/20180125035500/https://www. fda. gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM113411. pdf.
[4] COLLIGNON O，KOENIG F，KOCH A，et al. Adaptive designs in clinical trials：from scientific advice to marketing authorisation to the European medicine agency[J]. Trials，2018，19（1）：642.
[5] Food and Drug Administration. Draft guidance for industry-adaptive design clinical trials for drugs and biologics[EB/OL].（2010-02-26）[2022-08-10]. https://www.federalregister.gov/documents/2010/02/26/2010-3980/draft-guidance-for-industry-on-adaptive-design-clinical-trials-for-drugs-and-biologics-availability#:~:text=FDA%20is%20announcing%20the%20availability%20of%20a%20draft,design%20trials%20when%20used%20in%20drug%20development%20programs.
[6] Food and Drug Administration. Adaptive designs for clinical trials of drugs and biologics guidance for industry[EB/OL].（2019-11-29）[2022-08-10]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry.
[7] Food and Drug Administration. Adaptive designs for medical device clinical studies[EB/OL].（2018-10-01）[2022-08-10]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-designs-medical-device-clinical-studies.
[8] 国家药品监督管理局药品审评中心. 药物临床试验适应性设计指导原则（试行）[EB/OL].（2021-01-29）[2022-08-10]. https://www.cde.org.cn/zdyz/domesticinfopage?zdyzIdCODE=4409e51a403a911757af6caf3ecef129.
[9] CHOW S C，CHANG M，PONG A. Statistical consideration of adaptive methods in clinical development[J]. J Biopharm Stat，2005，15（4）：575-591.
[10] GALLO P，CHUANG-STEIN C，DRAGALIN V，et al. Adaptive designs in clinical drug development--an executive summary of the PhRMA working group[J]. J Biopharm Stat，2006，16（3）：275-283.
[11] CHOW S C. Adaptive clinical trial design[J/OL]. Annu Rev Med，2014，65：405-415[2022-08-10]. https://doi.org/10.1146/annurev-med-092012-112310.
[12] 陈峰，夏结来. 临床试验统计学[M]. 北京：人民卫生出版社，2018.
[13] WANG S J，HUNG H M，O'NEILL R. Paradigms for adaptive statistical information designs：practical experiences and strategies[J]. Stat Med，2012，31（25）：3011-3023.
[14] LAI T L，LAVORI P W，TSANG K W. Adaptive design of confirmatory trials：advances and challenges[J/OL]. Contemp Clin Trials，2015，45（Pt A）：93-102[2022-08-10]. https://doi.org/10.1016/j. cct.2015.06.007.
[15] LAI T L，LAVORI P W，SHIH M C. Adaptive trial designs[J/OL]. Annu Rev Pharmacol Toxicol，2012，52：101-110[2022-08-10]. https://doi.org/10.1146/annurev-pharmtox-010611-134504.
[16] BURNETT T，MOZGUNOV P，PALLMANN P，et al. Adding flexibility to clinical trial designs：an example-based guide to the practical use of adaptive designs[J]. BMC Med，2020，18（1）：352.
[17] KOJIMA M. Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial[J]. BMC Med Res Methodol，2022，22（1）：97.
[18] LYU J，CURRAN E，JI Y. Bayesian adaptive design for finding the maximum tolerated sequence of doses in multicycle dose-finding clinical trials[J/OL]. JCO Precis Oncol，2018，2：1-19[2022-08-10]. https://doi. org/10.1200/PO.18.00020.
[19] ORON A P，SOUTER M J，FLOURNOY N. Understanding research methods：up-and-down designs for dose-finding[J]. Anesthesiology，2022，137（2）：137-150.
[20] ALMASRI S，ZENATI M，HAMMAD A，et al. Adaptive dynamic therapy and survivorship for operable pancreatic cancer[J/OL]. JAMA Netw Open，2022，5（6）：e2218355[2022-08-10]. https://doi. org/10.1001/jamanetworkopen.2022.18355.
[21] CERQUEIRA F P，JESUS A M C，COTRIM M D. Adaptive design：a review of the technical，statistical，and regulatory aspects of implementation in a clinical trial[J]. Ther Innov Regul Sci，2020，54（1）：246-258.
[22] KAIRALLA J A，COFFEY C S，THOMANN M A，et al. Adaptive trial designs：a review of barriers and opportunities[J/OL]. Trials，2012，13：145[2022-08-10]. https://doi.org/10.1186/1745-6215-13-145.
[23] CHOW S C，CHANG M. Adaptive design methods in clinical trials-a review[J/OL]. Orphanet J Rare Dis，2008，3：11[2022-08-10]. https://doi.org/10. 1186/1750-1172-3-11.
[24] HILL M D，GOYAL M，MENON B K，et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke（ESCAPE-NA1）：a multicentre，double-blind，randomised controlled trial[J]. Lancet，2020，395（10227）：878-887.
[25] SWANSON C J，ZHANG Y，DHADDA S，et al. A randomized，double-blind，phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab，an anti-Aβ protofibril antibody[J]. Alzheimers Res Ther，2021，13（1）：80.
[26] JONES A E，PUSKARICH M A，SHAPIRO N I，et al. Effect of levocarnitine vs placebo as an adjunctive treatment for septic shock：the rapid administration of carnitine in sepsis（RACE）randomized clinical trial[J/OL]. JAMA Netw Open，2018，1（8）：e186076[2022-08-10]. https://doi.org/10.1001/jamanetworkopen.2018.6076.
[27] JOHNSTON S C，AMARENCO P，ALBERS G W，et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack[J]. N Engl J Med，2016，375（1）：35-43.
[28] JOHNSTON S C，AMARENCO P，DENISON H，et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA[J]. N Engl J Med，2020，383（3）：207-217.
[29] THORLUND K，HAGGSTROM J，PARK J J，et al. Key design considerations for adaptive clinical trials：a primer for clinicians[J/OL]. BMJ，2018，360：k698[2022-08-10]. https://doi.org/10.1136/bmj.k698.
[30] GRAYLING M J，WHEELER G M. A review of available software for adaptive clinical trial design[J]. Clinical Trials，2020，17（3）：323-331.
[31] DIMAIRO M，PALLMANN P，WASON J，et al. The adaptive designs CONSORT extension（ACE）statement：a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design[J/OL]. BMJ，2020，369：m115[2022-08-10]. https://doi.org/10.1136/bmj.m115.

[1]	蒲善宇, 周齐, 潘岳松. 我国脑血管病真实世界研究进展[J]. 中国卒中杂志, 2022, 17(12): 1289-1292.
[2]	张艳丽, 金奥铭, 潘岳松. 实效性临床试验：真实世界研究的随机化试验[J]. 中国卒中杂志, 2022, 17(12): 1299-1303.
[3]	胥芹, 张怡君, 田雪, 夏雪, 张晓丽, 李静, 王安心. 临床试验中的成组序贯设计[J]. 中国卒中杂志, 2022, 17(11): 1283-1287.
[4]	周齐, 杨凯璇, 姜英玉, 谷鸿秋. 基于登记/注册研究的随机对照试验[J]. 中国卒中杂志, 2022, 17(10): 1145-1151.
[5]	张润华, 潘岳松, 姜勇, 刘改芬. 脑血管病临床研究设计的方法简介和实例分析[J]. 中国卒中杂志, 2022, 17(01): 26-30.
[6]	陈玮琪，潘岳松，陈霞，柏峰，曹勇军，范玉华，胡波，刘军，毛玲，倪俊，曲辉，孙莉，孙中武，王丽华，吴波，吴丹红，谢春明，许予明，徐运，赵性泉，周国钰，朱以诚. 脑小血管病治疗药物临床试验设计规范专家共识[J]. 中国卒中杂志, 2021, 16(03): 288-297.
[7]	译者：熊云云，李子孝，丁玲玲，谷鸿秋，王春娟，王春雪，赵性泉，王拥军. 基于人工智能干预措施的临床试验方案指南：SPIRIT-AI扩展[J]. 中国卒中杂志, 2020, 15(11): 1228-1238.
[8]	李皓琳，姜勇. 临床研究数据管理与共享最新进展[J]. 中国卒中杂志, 2020, 15(06): 600-605.
[9]	王拥军. 临界点[J]. 中国卒中杂志, 2017, 12(10): 887-889.
[10]	郑华光，王伊龙，李姝雅，赵性泉，王春雪，王拥军. 药物临床试验方法学进展与质量管理规范教学新模式初步研究[J]. 中国卒中杂志, 2017, 12(09): 877-880.
[11]	王拥军. 卒中：回眸2015[J]. 中国卒中杂志, 2016, 11(01): 1-13.
[12]	王拥军. 十二年的轮回[J]. 中国卒中杂志, 2013, 8(03): 161-163.
[13]	刘改芬;王伊龙;武剑;徐蔚海;彭斌;倪俊;刘丽萍. 2011年国际卒中大会会议纪要[J]. , 2011, 6(04): 263-267.
[14]	谢丽华;侯敬天;侯玉立. 尤瑞克林治疗急性脑梗死Meta分析[J]. , 2011, 6(04): 287-296.
[15]	沈彦;梁建姝;林荔;郭军平. 研究护士的角色转换和工作模式探讨[J]. , 2010, 5(05): 56-58.